Analyse Beta Bionics, Inc. (BBNX) — Kairos Score 60/100

À propos de Beta Bionics, Inc.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Informations clés

🕴️ Activité des initiés (90 jours)

14 transactions — 0 achats et 14 ventes déclarés par les dirigeants de Beta Bionics, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur BBNX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur BBNX.

• Beta Bionics (BBNX) Stock Fair Value Rises After Mint Clearance And Analyst Target Changes
• Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.